Genentech fenebrutinib slashes MS relapses 51%
03/02/2026 – 01:10 AM – FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by…
Roche pill succeeds in another MS study, but approval questions linger
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free…
Roche MS drug fenebrutinib cuts relapses 51% in Phase III
Roche (OTCQX: RHHBY) reported that the pivotal Phase III study FENhance 1 met…
Roche Just Unleashed a Drug That Could Disrupt the Entire MS Market
This article first appeared on GuruFocus. Roche Holding (RHHBF) could be entering a new growth chapter after unveiling…